Objective. To examine the clinical implications of disturbed calcium metabolism in sarcoidosis and how the pathophysiology affects management strategies.
It has long been recognized that disturbances of calmately 10% of patients [7] , and more rarely tubular disorders such as nephrogenic diabetes insipidus [8] . cium metabolism can be a feature of sarcoidosis. Hypercalcaemia in association with sarcoidosis was first Symptomatic hypercalcaemia presenting with dehydration, polyuria and an altered conscious state is a rare described by Harrel et al. in 1939 [1] and since then an increased risk of hypercalcuria and reduced bone density but recognized complication of sarcoidosis.
Patients with sarcoidosis frequently require treatment has also been demonstrated [2] . This review will focus on the pathogenesis of abnormal calcium metabolism with prolonged courses of oral corticosteroids. In addition to the well-documented increased risk of osteoporand the impact it has in sarcoidosis. We will also outline management strategies for the most common clinical osis and fracture posed by corticosteroids [9] [10] [11] , there is some evidence that patients with sarcoidosis may have problems associated with disturbances in calcium homeostasis.
a greater incidence of reduced bone density than the general population prior to commencing treatment. In a study of corticosteroid-naïve subjects with sarcoidosis,
Clinical manifestations
Rizzato et al. [2] found that 61% of the subjects had a vertebral bone mineral density that was more than one Hypercalcuria is the most common defect of calcium standard deviation below normal, i.e. a Z score of less metabolism in sarcoidosis, with a prevalence of 40-62% than −1. in published series [3, 4] . Clinically significant hypercalcaemia is less frequent and is generally asymptomatic, occurring in approximately 5% of patients [5] . LongPathogenesis of abnormal calcium standing hypercalcaemia and hypercalcuria can cause metabolism nephrocalcinosis, which accounts for over half the Calcium homeostasis is a complex inter-relationship patients with sarcoidosis who have renal impairment [6 ] between gastrointestinal absorption, bone turnover, and is the major cause of chronic renal failure. Other renal excretion and protein binding. Tight regulation of renal complications of sarcoidosis due to abnormal this system is primarily controlled by levels of vitamin calcium metabolism include nephrolithiasis in approxi-D, parathyroid hormone (PTH ) and calcitonin, but is also influenced by thyroid and sex hormones. In sarco- 
Role of calcitriol in sarcoidosis.
Calcitriol has immunoregulatory properties and the raised levels in sarcoidosis may represent a favourable adaptive response [26 ] . High-affinity receptors for calcitriol are present on dendritic cells, lymphocytes and macrophages [27] , which are key immune effector cells in sarcoidosis [28] [29] [30] . Calcitriol has been shown to down-regulate the activation [31] and proliferation of lymphocytes, probably through the inhibition of interleukin-2 (IL-2) [32] and interferon-c (IFNc) [33] . Activation and proliferation of T-cells, spontaneously expressing the T helper 1 type cytokines IL-2 and IFNc, has been demonstrated repeatedly in sarcoidosis [34, 35] . Additional studies using gene knockout mice have demonstrated that IL-2 and especially IFNc are necessary for a granulomatous response [36] [37] [38] [39] . It is therefore conceivable that the calcitriol-mediated inhibition of IFNc and IL-2 is an attempt by the body to down-regulate T-cell activity at sites of inflammation.
Parathyroid hormone PTH release is primarily stimulated by low levels of ionized calcium and circulating vitamin D metabolites, but is also affected by b and histamine-2 receptor agonists as well as by magnesium. Apart from its previously mentioned role in up-regulating the 1-a hydroxylation of 25 [40] . There exist in the literature over 50 case reports of patients with hyperparathyroidism in excretion should be performed in all patients, as the absence of hypercalcaemia does not exclude the presence association with sarcoidosis [41, 42] , prompting some to suggest an association [43, 44] . Given the relative of significant hypercalcuria [49] . frequency of the two conditions [45] , it is more likely, Hypercalcaemia however, that they occur independently.
There are no firm guidelines governing which patients Parathyroid hormone-related peptide require treatment for hypercalcaemia. It is generally In 1987 a novel protein was identified in a number of accepted that a corrected serum calcium concentration patients with hypercalcaemia of malignancy [46 ] . This of >3.0 mmol/l or evidence of renal complications in protein had properties similar to PTH and was termed the presence of a lesser degree of hypercalcaemia is an parathyroid hormone-related peptide (PTHrP).
indication for therapy [50] . Patients with uncomplicated Precursor PTHrP is transcribed from a gene located on hypercalcaemia of <3.0 mmol/l probably do not require the short arm of chromosome 12, which then undergoes immediate treatment, but should be observed carefully tissue-specific post-translational modification to produce because calcium levels fluctuate [5] . three distinct peptide hormones, all of which share Severe hypercalcaemia is uncommon in sarcoidosis homology with PTH at its amino-terminal end and act [51] . Rarely, patients may present with renal failure, an on PTH receptors. In addition to its role in hypercalcaealtered mental state or a corrected serum calcium conmia of malignancy, PTHrP is involved in the differenticentration of >3.50 mmol/l, requiring emergency treatation of human cells and in calcium metabolism in ment. [48] , two cytokines that are no effect on 1a-hydroxylase in the renal tubular cell, up-regulated in sarcoidosis [30, 48] . It is possible that they are potent inhibitors of this enzyme in the macroTNFa and IL-6 produced by macrophages have autophage [25, 54] . Corticosteroids also bind to cytokine crine actions, up-regulating PTHrP expression and promoter regions in the macrophage nucleus, downtherefore increasing calcitriol synthesis.
regulating IL-2 and IFNc expression [55] and resulting in reduced PTHrP production by macrophages. Most patients present with the management problem Management of abnormal calcium of asymptomatic low-grade hypercalcaemia, the treathomeostasis ment of which aims to prevent long-term renal and bone complications. It is accepted practice that all patients The following investigations are necessary to assess calcium homeostasis in patients presenting with sarcobe advised to minimize their exposure to sunlight, avoid fish oils rich in vitamin D and maintain a fluid intake idosis (Fig. 1) . Serum calcium and albumin should be measured so that an estimate of the ionized calcium of >2 l per day [51, 56 ] . Although many centres advise avoiding dairy products and calcium-containing antacids level can be calculated, as well as 24-h urine collection for calcium excretion. If renal impairment, hypercal- [51] , it is not our practice to recommend a low-calcium diet as there is little evidence that it affects calcium caemia or significant hypercalcuria (>400 mg/24 h) is detected, 24-h creatinine clearance and abdominal balance and it may increase the risk of nephrolithiasis. A moderate dose of prednisolone (15-25 mg/day) is an ultrasound investigations should be performed to exclude urolithiasis or nephrocalcinosis. Hypercalcaemia effective treatment for hypercalcaemia and, if there is an alternative indication for corticosteroids, is the logical detected in a patient presenting with acute sarcoidosis requires no further assessment, and studies suggest that first-line therapy. Because corticosteroids may exacerbate hypercalcuria [57] , it is our practice to repeat the monitoring the response to corticosteroid therapy is acceptable practice [49] . The hypercalcaemia of primary 24-h measurement of urinary calcium excretion soon after commencing therapy. hyperparathyroidism is not responsive to corticosteroids Patients who do not have an indication for cortico- [70] . Increased oxalate absorption results in higher levels steroids other than hypercalcaemia, or in whom corticoof oxaluria. Oxalate saturation increases rapidly with steroids are relatively contraindicated, may be started small increases in urinary oxalate [71] , so any factor on ketoconazole. Ketoconazole is an imidazole antithat increases oxaluria may contribute to the formation fungal agent that inhibits the cytochrome P450-linked of calcium oxalate stones. enzyme systems involved in steroid synthesis [53, 58] .
Corticosteroids generally reduce hypercalcuria, and Recognition that 25(OH )D 3 -1a-hydroxylase is a P450-they do this through the inhibition of calcitriol synthesis. dependent enzyme system led to the use of ketoconazole If there is isolated hypercalcuria associated with nephroin primary hyperparathyroidism as a means of reducing lithiasis and no other indication for corticosteroids, a calcitriol synthesis [59, 60] . Although the literature therapeutic trial of a thiazide diuretic is indicated. supporting the use of ketoconazole in combination with Thiazide diuretics act on the distal convoluted tubule to corticosteroids for hypercalcaemic sarcoidosis is limited inhibit calcium excretion, and have been shown in two to isolated case reports [53, 56 ] , it has been our experilarge randomized trials to reduce the risk of recurrent ence that the addition of ketoconazole results in the nephrolithiasis in idiopathic hypercalcuria by approxidose of corticosteroids being significantly reduced in all mately 50% [72, 73] . Although thiazide diuretics have patients and ceased in some. Hydroxychloroquine also the potential to affect the lipid profile adversely and causes inhibition of 25(OH )D 3 -1a-hydroxylase [61] and there are no large trials detailing their effectiveness in can be considered for patients who are intolerant of sarcoidosis, we feel their use is justified in patients with ketoconazole or who develop abnormal liver function hypercalcuria when there is a history of nephrolithiasis. tests. Methotrexate and azathioprine are frequently used as adjuvant therapy for patients with sarcoidosis. Osteoporosis Although they do not have any direct effect on calcium
The primary and secondary prevention of glucocortmetabolism, they may help control hypercalcaemia by icoid-induced osteoporosis in sarcoidosis is often comreducing the granuloma burden.
plicated by coexistent disturbances in calcium metabolism. Given the increased frequency of hypercalHypercalcuria caemia, hypercalcuria and possibly reduced bone denThe pathogenesis of hypercalcuria in sarcoidosis is not sity, should the management of osteoporosis in fully understood. The maximum reabsorption rate for sarcoidosis differ significantly from that outlined in calcium is not increased and it is felt that hypercalcuria recently published recommendations for the manageis due mainly to the capacity of the tubular reabsorptive ment of glucocorticoid-induced osteoporosis? In the mechanisms for calcium being exceeded [62] . Renal absence of evidence specifically addressing the issue of tubular cells do not express receptors for calcitriol and osteoporosis treatment in sarcoidosis, we largely follow elevated levels of calcitriol contribute to hypercalcuria the recommendations outlined by Eastell et al.
[74] for only indirectly, through increased gastrointestinal the management of glucocorticoid-induced osteoporosis, absorption and bone resorption.
with some minor modifications to accommodate the In general, the management of hypercalcuria involves young age of many patients and the disturbances in minimizing the risk of nephrolithiasis, through maintencalcium metabolism unique to sarcoidosis. In this section ance of a high urinary volume and by minimizing we do not intend to provide a comprehensive review of exposure to sunlight. As mentioned previously, recent glucocorticoid-induced osteoporosis management, but studies have questioned the utility of a low-calcium diet rather plan to highlight how current guidelines can be in hypercalcuria. Up to 85% of renal stones in the adapted for sarcoidosis patients. general population contain calcium [63] , an observation Initial assessment. In addition to the routine investithat reasonably reflects stone composition in patients gations to exclude a secondary cause of osteoporosis, with sarcoidosis [51] . The hypothesis that dietary intake such as hypogonadism, osteomalacia, myeloma and of calcium influences stone formation is based on the thyrotoxicosis, we perform a 24-h urinary calcium collecobservation that approximately one third of patients tion. Although earlier guidelines recommended this with nephrolithiasis have primary hypercalcuria [64] , investigation [75] , it was seldom performed and has and limiting dietary calcium intake will reduce stone been omitted from current guidelines. It is our practice formation by decreasing urinary calcium excretion [65] .
to treat significant hypercalcuria prior to commencing Despite this relationship, two large-scale epidemiological osteoporosis therapies that may exacerbate this problem. studies have failed to demonstrate that higher mean Bone mineral density. When corticosteroids are indicalcium intakes correlate with a higher rate of nephrolicated for sarcoidosis, patients generally receive thiasis [66, 67] . In fact, one study published by Curhan >15 mg/day for >6 months, which places them at high et al. [68] found an inverse relationship that reached risk of developing osteoporosis. We therefore feel that, statistical significance. While a protective effect of dietwhenever possible, dual-energy X-ray-based absorptiary calcium may seem counterintuitive, the association ometry of the lumbar spine and femoral neck should be may have a physiological explanation. It has been noted performed. The presence of lifestyle factors predisposing that gastrointestinal absorption of oxalate increases with to osteoporosis makes the assessment of bone density intraluminal binding of calcium to fat in malabsorptive syndromes [69] and with dietary restriction of calcium more necessary.
Therapeutic interventions. Although primary prevenbased on current management guidelines for glucocorttion studies suggest that cholecalciferol is not entirely icoid-induced osteoporosis. Although many agents used effective in preventing glucocorticoid-induced bone loss for the prevention of osteoporosis have the potential to [76 ], it is well tolerated by patients and is used routinely cause problems in sarcoidosis patients with abnormal in our sarcoidosis clinic once hypercalcaemia has been calcium metabolism, clinical experience has found these excluded. There is evidence that cholecalciferol can cause agents to be relatively safe. Further investigation of hypercalcaemia in patients with sarcoidosis [40, 41] , metabolic bone disease in sarcoidosis is required to although clinical experience suggests that it can be given confirm the accuracy of existing data that suggest that safely in this population. As a precaution, however, we steroid-naïve patients have an increased risk of osteoproutinely measure serum calcium and urinary calcium enia and to find out whether there are important differexcretion 1 month after commencing therapy.
ences in the mechanisms of bone loss in this population. Unfortunately, because of the young age of most sarcoidosis patients, the benefits of hormone replacement for hypogonadism can seldom be exploited. Currently avail-
